The BioSig Tech medical device company develops a proprietary biomedical signal processing technology platform, called PURE EP™ System. This platform is designed for acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels in order to improve Atrial Fibrillation and Ventricular Tachycardia. The PURE EP™ System has increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures.
Claim your business profile now and gain access to all features and respond to customer reviews.
Medical device company developing a biomedical signal processing platform to address unmet technology needs for the $4.6 billion electrophysiology market. $BSGM
